Journal of Personalised Medecine
by Laura Maintz
1,2,*,† [ORCID] , Thomas Bieber
1,2,3,†, Helen D. Simpson
4 and Anne-Laure Demessant-Flavigny
5 [ORCID]

1 Department of Dermatology and Allergy, University Hospital Bonn, 53127 Bonn, Germany
2 Christine Kühne Center for Allergy Research and Education Davos (CK-CARE), 7265 Davos, Switzerland
3 Davos Biosciences, Herman-Burchard-Str. 9, CH-7265 Davos Wolfgang, Switzerland
4 My Word Medical Writing, 13260 Cassis, France
5 La Roche-Posay International, 92300 Levallois-Perret, France*
Author to whom correspondence should be addressed.
†These authors contributed equally to this work.
J. Pers. Med. 2022, 12(6), 893; https://doi.org/10.3390/jpm12060893
Submission received: 15 April 2022 / Revised: 20 May 2022 / Accepted: 24 May 2022 / Published: 28 May 2022

Abstract

Atopic dermatitis (AD) affects up to 20% of children and is considered the starting point of the atopic march with the development of food allergy, asthma, and allergic rhinitis. The heterogeneous phenotype reflects distinct and/or overlapping pathogenetic mechanisms with varying degrees of epidermal barrier disruption, activation of different T cell subsets and dysbiosis of the skin microbiome. Here, we review current evidence suggesting a systemic impact of the cutaneous inflammation in AD together with a higher risk of asthma and other comorbidities, especially in severe and persistent AD.

Find out more.